Faculty
Oncology Division
Alphabetical list (active faculty):   
Cynthia X. Ma

Cynthia X. Ma, MD, PhD

Professor

Department of Medicine

Oncology Division

Medical Oncology

Clinical Interests

  • Breast cancer

Research Interests

  • Pharmacogenomics of anticancer agents
  • Predictive biomarkers
  • Developmental therapeutics

Contact

  • 314-747-3096 (office)
  • 314-362-7086 (fax)
  • Division of Oncology
    Mail Stop 8076-0041-03
    Washington University
    660 South Euclid Avenue
    St. Louis, MO 63110
  • Room 3311, Couch Biomedical Research Building (office)

Peer-reviewed Articles

  • Intermittent Fasting in the Prevention and Treatment of Cancer
    Clifton KK, Ma CX, Fontana L, Peterson LL
    CA Cancer J Clin 2021 Nov;71(6):527-546
  • Serial Single-Cell Genomics Reveals Convergent Subclonal Evolution of Resistance as Early-Stage Breast Cancer Patients Progress on Endocrine Plus CDK4/6 Therapy
    Griffiths JI, Chen J, Cosgrove PA, O'Dea A, Sharma P, Ma C, Trivedi M, Kalinsky K, Wisinski KB, O'Regan R, Makhoul I, Spring LM, Bardia A, Adler FR, Cohen AL, Chang JT, Khan QJ, Bild AH
    Nat Cancer 2021 Jun;2(6):658-671
  • A First-In-Human Phase 1 Study of a Novel Selective Androgen Receptor Modulator (SARM), RAD140, in ER+/HER2- Metastatic Breast Cancer
    LoRusso P, Hamilton E, Ma C, Vidula N, Bagley RG, Troy S, Annett M, Yu Z, Conlan MG, Weise A
    Clin Breast Cancer 2021 Aug 20; [Epub ahead of print]
  • Effective Treatment of Established Bone Metastases Can Be Achieved by Combinatorial Osteoclast Blockade and Depletion of Granulocytic Subsets
    Capietto AH, Lee S, Clever D, Eul E, Ellis H, Ma CX, Faccio R
    Cancer Immunol Res 2021 Sep 22; [Epub ahead of print]
  • Breast Cancer, HER2 Mutations, and Overcoming Drug Resistance
    Bose R, Ma CX
    N Engl J Med 2021 Sep 23;385(13):1241-1243
  • Phase I Study of Docetaxel and Temsirolimus in Refractory Solid Tumors
    Amin M, Gao F, Terrero G, Picus J, Wang-Gillam A, Suresh R, Ma C, Tan B, Baggstrom M, Naughton MJ, Trull L, Belanger S, Fracasso PM, Lockhart AC
    Am J Clin Oncol 2021 Sep 1;44(9):443-448
  • Comprehensive Characterization of 536 Patient-Derived Xenograft Models Prioritizes Candidates For Targeted Treatment
    Sun H, Cao S, Mashl RJ, Mo CK, Zaccaria S, Wendl MC, Davies SR, Bailey MH, Primeau TM, Hoog J, Mudd JL, Dean DA 2nd, Patidar R, Chen L, Wyczalkowski MA, Jayasinghe RG, Rodrigues FM, Terekhanova NV, Li Y, Lim KH, Wang-Gillam A, Van Tine BA, Ma CX, Aft R, Fuh KC, Schwarz JK, Zevallos JP, Puram SV, DiPersio JF, Davis-Dusenbery B, Ellis MJ, Lewis MT, Davies MA, Herlyn M, Fang B, Roth JA, Welm AL, Welm BE, Meric-Bernstam F, Chen F, Fields RC, Li S, Govindan R, Doroshow JH, Moscow JA, Evrard YA, Chuang JH, Raphael BJ, Ding L
    NCI PDXNET Consortium

    Nat Commun 2021 Aug 24;12(1):5086
  • Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women With HR(+)/HER2(-) Advanced Breast Cancer After Progression on CDK4/6 Inhibitors (TRINITI-1)
    Bardia A, Hurvitz SA, DeMichele A, Clark AS, Zelnak A, Yardley DA, Karuturi M, Sanft T, Blau S, Hart L, Ma C, Rugo HS, Purkayastha D, Moulder S
    Clin Cancer Res 2021 Aug 1;27(15):4177-4185
  • The Human Tumor Atlas Network: Charting Tumor Transitions Across Space and Time at Single-Cell Resolution
    Rozenblatt-Rosen O, Regev A, Oberdoerffer P, Nawy T, Hupalowska A, Rood JE, Ashenberg O, Cerami E, Coffey RJ, Demir E, Ding L, Esplin ED, Ford JM, Goecks J, Ghosh S, Gray JW, Guinney J, Hanlon SE, Hughes SK, Hwang ES, Iacobuzio-Donahue CA, Jane-Valbuena J, Johnson BE, Lau KS, Lively T, Mazzilli SA, Pe'er D, Santagata S, Shalek AK, Schapiro D, Snyder MP, Sorger PK, Spira AE, Srivastava S, Tan K, West RB, Williams EH
    Human Tumor Atlas Network (Contributors include: Ma CX)

    Cell 2020 Apr 16;181(2):236-249
  • CDK4/6 Inhibition Reprograms the Breast Cancer Enhancer Landscape by Stimulating AP-1 Transcriptional Activity
    Watt AC, Cejas P, DeCristo MJ, Metzger-Filho O, Lam EYN, Qiu X, BrinJones H, Kesten N, Coulson R, Font-Tello A, Lim K, Vadhi R, Daniels VW, Montero J, Taing L, Meyer CA, Gilan O, Bell CC, Korthauer KD, Giambartolomei C, Pasaniuc B, Seo JH, Freedman ML, Ma C, Ellis MJ, Krop I, Winer E, Letai A, Brown M, Dawson MA, Long HW, Zhao JJ, Goel S
    Nat Cancer 2021 Jan;2(1):34-48
  • A Microfluidic-Based Filtration System to Enrich for Bone Marrow Disseminated Tumor Cells From Breast Cancer Patients
    Pillai SG, Siddappa CM, Ma C, Snider J, Kaushal M, Watson MA, Aft R
    PLoS One 2021 May 14;16(5):e0246139
  • Early Assessment Window for Predicting Breast Cancer Neoadjuvant Therapy Using Biomarkers, Ultrasound, and Diffuse Optical Tomography
    Zhu Q, Ademuyiwa FO, Young C, Appleton C, Covington MF, Ma C, Sanati S, Hagemann IS, Mostafa A, Uddin KMS, Grigsby I, Frith AE, Hernandez-Aya LF, Poplack SS
    Breast Cancer Res Treat 2021 Aug;188(3):615-630
  • Evaluation of Racial/Ethnic Differences in Treatment and Mortality Among Women With Triple-Negative Breast Cancer
    Cho B, Han Y, Lian M, Colditz GA, Weber JD, Ma C, Liu Y
    JAMA Oncol 2021 Jul 1;7(7):1016-1023
  • Immunogenomic Profiling and Pathological Response Results From a Clinical Trial of Docetaxel and Carboplatin in Triple-Negative Breast Cancer
    Ademuyiwa FO, Chen I, Luo J, Rimawi MF, Hagemann IS, Fisk B, Jeffers G, Skidmore ZL, Basu A, Richters M, Ma CX, Weilbaecher K, Davis J, Suresh R, Peterson LL, Bose R, Bagegni N, Rigden CE, Frith A, Rearden TP, Hernandez-Aya LF, Roshal A, Clifton K, Opyrchal M, Akintola-Ogunremi O, Lee BH, Ferrando-Martinez S, Church SE, Anurag M, Ellis MJ, Gao F, Gillanders W, Griffith OL, Griffith M
    Breast Cancer Res Treat 2021 Aug;189(1):187-202
  • Physical Activity, Weight, and Outcomes in Patients Receiving Chemotherapy for Metastatic Breast Cancer (C40502/Alliance)
    Ligibel JA, Huebner L, Rugo HS, Burstein HJ, Toppmeyer DL, Anders CK, Ma C, Barry WT, Suman V, Carey LA, Partridge AH, Hudis CA, Winer EP
    JNCI Cancer Spectr 2021 Apr 12;5(3):pkab025
  • Glembatumumab Vedotin for Patients With Metastatic, GpNMB Overexpressing, Triple-Negative Breast Cancer ("METRIC"): A Randomized Multicenter Study
    Vahdat LT, Schmid P, Forero-Torres A, Blackwell K, Telli ML, Melisko M, Mobus V, Cortes J, Montero AJ, Ma C, Nanda R, Wright GS, He Y, Hawthorne T, Bagley RG, Halim AB, Turner CD, Yardley DA
    NPJ Breast Cancer 2021 May 20;7(1):57
  • Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy
    Magbanua MJM, Hendrix LH, Hyslop T, Barry WT, Winer EP, Hudis C, Toppmeyer D, Carey LA, Partridge AH, Pierga JY, Fehm T, Vidal-Martinez J, Mavroudis D, Garcia-Saenz JA, Stebbing J, Gazzaniga P, Manso L, Zamarchi R, Antelo ML, Mattos-Arruda L, Generali D, Caldas C, Munzone E, Dirix L, Delson AL, Burstein HJ, Qadir M, Ma C, Scott JH, Bidard FC, Park JW, Rugo HS
    J Natl Cancer Inst 2021 Apr 6;113(4):443-452
  • Clinical Outcomes With Abemaciclib After Prior CDK4/6 Inhibitor Progression in Breast Cancer: A Multicenter Experience
    Wander SA, Han HS, Zangardi ML, Niemierko A, Mariotti V, Kim LSL, Xi J, Pandey A, Dunne S, Nasrazadani A, Kambadakone A, Stein C, Lloyd MR, Yuen M, Spring LM, Juric D, Kuter I, Sanidas I, Moy B, Mulvey T, Vidula N, Dyson NJ, Ellisen LW, Isakoff S, Wagle N, Brufsky A, Kalinsky K, Ma CX, O'Shaughnessy J, Bardia A
    J Natl Compr Canc Netw 2021 Mar 24:1-8; [Epub ahead of print]
  • Cisplatin +/- Rucaparib After Preoperative Chemotherapy in Patients With Triple-Negative or BRCA Mutated Breast Cancer
    Kalra M, Tong Y, Jones DR, Walsh T, Danso MA, Ma CX, Silverman P, King MC, Badve SS, Perkins SM, Miller KD
    NPJ Breast Cancer 2021 Mar 22;7(1):29
  • A Priori Activation of Apoptosis Pathways of Tumor (AAAPT) Technology: Development of Targeted Apoptosis Initiators for Cancer Treatment
    Pandurangi RS, Tomasetti M, Verapazham ST, Paulmurugan R, Ma C, Rajput S, Anjanappa M, Nakshatri H
    PLoS One 2021 Feb 8;16(2):e0225869
  • Cancer-Associated Exportin-6 Upregulation Inhibits the Transcriptionally Repressive and Anticancer Effects of Nuclear Profilin-1
    Zhu C, Kim SJ, Mooradian A, Wang F, Li Z, Holohan S, Collins PL, Wang K, Guo Z, Hoog J, Ma CX, Oltz EM, Held JM, Shao J
    Cell Rep 2021 Feb 16;34(7):108749
  • RNA Based Approaches to Profile Oncogenic Pathways From Low Quantity Samples to Drive Precision Oncology Strategies
    van de Stolpe A, Verhaegh W, Blay JY, Ma CX, Pauwels P, Pegram M, Prenen H, De Ruysscher D, Saba NF, Slovin SF, Willard-Gallo K, Husain H
    Front Genet 2021 Feb 5;11:598118
  • Association of PET-Based Estradiol-Challenge Test for Breast Cancer Progesterone Receptors With Response to Endocrine Therapy
    Dehdashti F, Wu N, Ma CX, Naughton MJ, Katzenellenbogen JA, Siegel BA
    Nat Commun 2021 Feb 2;12(1):733
  • Prolactin and Estrogen Levels in Postmenopausal Women Receiving Aripiprazole Augmentation Treatment for Depression
    Rahman T, Patrick C, Ma C, Nicol GE, Reynolds CF 3rd, Mulsant BH, Hartz SM, Yingling M, Lenze EJ
    J Clin Psychopharmacol 2021 Jan/Feb 01;41(1):31-35
  • Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients With PIK3CA-Mutant Cancers
    Jhaveri K, Chang MT, Juric D, Saura C, Gambardella V, Melnyk A, Patel MR, Ribrag V, Ma CX, Aljumaily R, Bedard PL, Sachdev JC, Dunn L, Won H, Bond J, Jones S, Savage HM, Scaltriti M, Wilson TR, Wei MC, Hyman DM
    Clin Cancer Res 2021 Jan 15;27(2):447-459
  • Conservation of Copy Number Profiles During Engraftment and Passaging of Patient-Derived Cancer Xenografts
    Woo XY, Giordano J, Srivastava A, Zhao ZM, Lloyd MW, de Bruijn R, Suh YS, Patidar R, Chen L, Scherer S, Bailey MH, Yang CH, Cortes-Sanchez E, Xi Y, Wang J, Wickramasinghe J, Kossenkov AV, Rebecca VW, Sun H, Mashl RJ, Davies SR, Jeon R, Frech C, Randjelovic J, Rosains J, Galimi F, Bertotti A, Lafferty A, O'Farrell AC, Modave E, Lambrechts D, Ter Brugge P, Serra V, Marangoni E, El Botty R, Kim H, Kim JI, Yang HK, Lee C, Dean DA 2nd, Davis-Dusenbery B, Evrard YA, Doroshow JH, Welm AL, Welm BE, Lewis MT, Fang B, Roth JA, Meric-Bernstam F, Herlyn M, Davies MA, Ding L, Li S, Govindan R, Isella C, Moscow JA, Trusolino L, Byrne AT, Jonkers J, Bult CJ, Medico E, Chuang JH
    PDXNET Consortium (Contributors include: Ma CX)

    Nat Genet 2021 Jan;53(1):86-99
  • Mutation Profile Differences in Younger and Older Patients With Advanced Breast Cancer Using Circulating Tumor DNA (CtDNA)
    Clifton K, Luo J, Tao Y, Saam J, Rich T, Roshal A, Frith A, Rigden C, Ademuyiwa F, Weilbaecher K, Hernandez-Aya L, Peterson LL, Bagegni N, Suresh R, Bose R, Opyrchal M, Wildes TM, Ma C
    Breast Cancer Res Treat 2021 Feb;185(3):639-646
  • Phase I Study of Liposomal Irinotecan in Patients With Metastatic Breast Cancer: Findings From the Expansion Phase
    Sachdev JC, Munster P, Northfelt DW, Han HS, Ma C, Maxwell F, Wang T, Belanger B, Zhang B, Moore Y, Thiagalingam A, Anders C
    Breast Cancer Res Treat 2021 Feb;185(3):759-771
  • Cisplatin-Associated Neuropathy Characteristics Compared With Those Associated With Other Neurotoxic Chemotherapy Agents (Alliance A151724)
    Albany C, Dockter T, Wolfe E, Le-Rademacher J, Wagner-Johnston N, Einhorn L, Lafky JM, Smith E, Pachman D, Staff N, Ma C, Loprinzi CL, Costello BA
    Support Care Cancer 2021 Feb;29(2):833-840
  • Proteomic Resistance Biomarkers for PI3K Inhibitor in Triple Negative Breast Cancer Patient-Derived Xenograft Models
    Guo Z, Primeau T, Luo J, Zhang C, Sun H, Hoog J, Gao F, Huang S, Edwards DP, Davies SR, Aft R, Ding L, Ellis MJ, Li S, Ma CX
    Cancers (Basel) 2020 Dec 21;12(12)
  • Evidence-Based Guidelines for Managing Patients With Primary ER+ HER2- Breast Cancer Deferred From Surgery Due to the COVID-19 Pandemic
    Dowsett M, Ellis MJ, Dixon JM, Gluz O, Robertson J, Kates R, Suman VJ, Turnbull AK, Nitz U, Christgen M, Kreipe H, Kuemmel S, Bliss JM, Barry P, Johnston SR, Jacobs SA, Ma CX, Smith IE, Harbeck N
    NPJ Breast Cancer 2020 Jun 8;6:21
  • Predictors of Distant Metastases in Triple-Negative Breast Cancer Without Pathologic Complete Response After Neoadjuvant Chemotherapy
    Kennedy WR, Tricarico C, Gabani P, Weiner AA, Altman MB, Ochoa LL, Thomas MA, Margenthaler JA, Sanati S, Peterson LL, Ma CX, Ademuyiwa FO, Zoberi I
    J Natl Compr Canc Netw 2020 Mar;18(3):288-296
  • Microscaled Proteogenomic Methods for Precision Oncology
    Satpathy S, Jaehnig EJ, Krug K, Kim BJ, Saltzman AB, Chan DW, Holloway KR, Anurag M, Huang C, Singh P, Gao A, Namai N, Dou Y, Wen B, Vasaikar SV, Mutch D, Watson MA, Ma CX, Ademuyiwa FO, Rimawi MF, Schiff R, Hoog J, Jacobs S, Malovannaya A, Hyslop T, Clauser KR, Mani DR, Perou CM, Miles G, Zhang B, Gillette MA, Carr SA, Ellis MJ
    Nat Commun 2020 Jan 27;11(1):532
  • Phase 1 Dose Escalation Study of the Allosteric AKT Inhibitor BAY 1125976 in Advanced Solid Cancer-Lack of Association Between Activating AKT Mutation and AKT Inhibition-Derived Efficacy
    Schneeweiss A, Hess D, Joerger M, Varga A, Moulder S, Tsimberidou AM, Ma C, Hurvitz SA, Rentzsch C, Rudolph M, Thiele S, Boix O, Wilkinson G, Lagkadinou E, Ocker M
    Cancers (Basel) 2019 Dec 10;11(12)
  • Identifying ERBB2 Activating Mutations in HER2-Negative Breast Cancer: Clinical Impact of Institute-Wide Genomic Testing and Enrollment in Matched Therapy Trials
    Exman P, Garrido-Castro AC, Hughes ME, Freedman RA, Li T, Trippa L, Bychkovsky BL, Barroso-Sousa R, Di Lascio S, Mackichan C, Lloyd MR, Krevalin M, Cerami E, Merrill MS, Santiago R, Crowley L, Kuhnly N, Files J, Lindeman NI, MacConaill LE, Kumari P, Tolaney SM, Krop IE, Bose R, Johnson BE, Ma CX, Dillon DA, Winer EP, Wagle N, Lin NU
    JCO Precis Oncol 2019 Nov 15;3
  • Randomized Controlled Trial of High-Dose Versus Standard-Dose Vitamin D3 for Prevention of Aromatase Inhibitor-Induced Arthralgia
    Niravath P, Hilsenbeck SG, Wang T, Jiralerspong S, Nangia J, Pavlick A, Ademuyiwa FO, Frith AE, Ma CX, Park H, Rigden CE, Suresh R, Ellis M, Kent Osborne C, Rimawi MF
    Breast Cancer Res Treat 2019 Sep;177(2):427-435
  • PI3K Inhibition Enhances the Anti-Tumor Effect of Eribulin in Triple Negative Breast Cancer
    Rajput S, Guo Z, Li S, Ma CX
    Oncotarget 2019 Jun 4;10(38):3667-3680
  • Treatment Response as Predictor for Brain Metastasis in Triple Negative Breast Cancer: A Score-Based Model
    Gabani P, Weiner AA, Hernandez-Aya LF, Khwaja S, Roach MC, Ochoa LL, Mullen D, Thomas MA, Matesa MA, Margenthaler JA, Cyr AE, Naughton MJ, Ma CX, Sanati S, Zoberi I
    Breast J 2019 May;25(3):363-372
  • Predictors of Locoregional Recurrence After Failure to Achieve Pathologic Complete Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
    Gabani P, Merfeld E, Srivastava AJ, Weiner AA, Ochoa LL, Mullen D, Thomas MA, Margenthaler JA, Cyr AE, Peterson LL, Naughton MJ, Ma C, Zoberi I
    J Natl Compr Canc Netw 2019 Apr 1;17(4):348-356
  • Neutrophil-To-Lymphocyte Ratio as a Predictor of Survival in Patients With Triple-Negative Breast Cancer
    Patel DA, Xi J, Luo J, Hassan B, Thomas S, Ma CX, Campian JL
    Breast Cancer Res Treat 2019 Apr;174(2):443-452
  • Retrospective Analysis of Treatment Patterns and Effectiveness of Palbociclib and Subsequent Regimens in Metastatic Breast Cancer
    Xi J, Oza A, Thomas S, Ademuyiwa F, Weilbaecher K, Suresh R, Bose R, Cherian M, Hernandez-Aya L, Frith A, Peterson L, Luo J, Krishnamurthy J, Ma CX
    J Natl Compr Canc Netw 2019 Feb;17(2):141-147
  • Acquired HER2 Mutations in ER(+) Metastatic Breast Cancer Confer Resistance to Estrogen Receptor-Directed Therapies
    Nayar U, Cohen O, Kapstad C, Cuoco MS, Waks AG, Wander SA, Painter C, Freeman S, Persky NS, Marini L, Helvie K, Oliver N, Rozenblatt-Rosen O, Ma CX, Regev A, Winer EP, Lin NU, Wagle N
    Nat Genet 2019 Feb;51(2):207-216
  • Cytokine Sensitivity Screening Highlights BMP4 Pathway Signaling as a Therapeutic Opportunity in ER(+) Breast Cancer
    Shee K, Jiang A, Varn FS, Liu S, Traphagen NA, Owens P, Ma CX, Hoog J, Cheng C, Golub TR, Straussman R, Miller TW
    FASEB J 2019 Feb;33(2):1644-1657
  • Safety and Pharmacokinetics of MM-302, a HER2-Targeted Antibody-Liposomal Doxorubicin Conjugate, in Patients With Advanced HER2-Positive Breast Cancer: A Phase 1 Dose-Escalation Study
    Munster P, Krop IE, LoRusso P, Ma C, Siegel BA, Shields AF, Molnar I, Wickham TJ, Reynolds J, Campbell K, Hendriks BS, Adiwijaya BS, Geretti E, Moyo V, Miller KD
    Br J Cancer 2018 Oct;119(9):1086-1093
  • Male Breast Cancer: An Updated Surveillance, Epidemiology, and End Results Data Analysis
    Liu N, Johnson KJ, Ma CX
    Clin Breast Cancer 2018 Oct;18(5):e997-e1002
  • Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer
    Lei JT, Shao J, Zhang J, Iglesia M, Chan DW, Cao J, Anurag M, Singh P, He X, Kosaka Y, Matsunuma R, Crowder R, Hoog J, Phommaly C, Goncalves R, Ramalho S, Peres RMR, Punturi N, Schmidt C, Bartram A, Jou E, Devarakonda V, Holloway KR, Lai WV, Hampton O, Rogers A, Tobias E, Parikh PA, Davies SR, Li S, Ma CX, Suman VJ, Hunt KK, Watson MA, Hoadley KA, Thompson EA, Chen X, Kavuri SM, Creighton CJ, Maher CA, Perou CM, Haricharan S, Ellis MJ
    Cell Rep 2018 Aug 7;24(6):1434-1444e7
  • Integrative Omics Analyses Broaden Treatment Targets in Human Cancer
    Sengupta S, Sun SQ, Huang KL, Oh C, Bailey MH, Varghese R, Wyczalkowski MA, Ning J, Tripathi P, McMichael JF, Johnson KJ, Kandoth C, Welch J, Ma C, Wendl MC, Payne SH, Fenyo D, Townsend RR, DiPersio JF, Chen F, Ding L
    Genome Med 2018 Jul 27;10(1):60
  • Mass Spectrometry-Based Proteomics Reveals Potential Roles of NEK9 and MAP2K4 in Resistance to PI3K Inhibition in Triple-Negative Breast Cancers
    Mundt F, Rajput S, Li S, Ruggles KV, Mooradian AD, Mertins P, Gillette MA, Krug K, Guo Z, Hoog J, Erdmann-Gilmore P, Primeau T, Huang S, Edwards DP, Wang X, Wang X, Kawaler E, Mani DR, Clauser KR, Gao F, Luo J, Davies SR, Johnson GL, Huang KL, Yoon CJ, Ding L, Fenyo D, Ellis MJ, Townsend RR, Held JM, Carr SA, Ma CX
    Cancer Res 2018 May 15;78(10):2732-2746
  • A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Advanced HER2-Negative Breast Cancer and Elevated C-Reactive Protein, a Marker of Systemic Inflammation
    O'Shaughnessy J, DeMichele A, Ma CX, Richards P, Yardley DA, Wright GS, Kalinsky K, Steis R, Diab S, Kennealey G, Geschwindt R, Jiang W, Rugo HS
    Breast Cancer Res Treat 2018 Aug;170(3):547-557
  • Breast and Pancreatic Cancer Interrupt IRF8-Dependent Dendritic Cell Development to Overcome Immune Surveillance
    Meyer MA, Baer JM, Knolhoff BL, Nywening TM, Panni RZ, Su X, Weilbaecher KN, Hawkins WG, Ma C, Fields RC, Linehan DC, Challen GA, Faccio R, Aft RL, DeNardo DG
    Nat Commun 2018 Mar 28;9(1):1250
  • Evaluation of [(89)Zr]trastuzumab-PET/CT in Differentiating HER2-Positive From HER2-Negative Breast Cancer
    Dehdashti F, Wu N, Bose R, Naughton MJ, Ma CX, Marquez-Nostra BV, Diebolder P, Mpoy C, Rogers BE, Lapi SE, Laforest R, Siegel BA
    Breast Cancer Res Treat 2018 Jun;169(3):523-530
  • Preclinical PET Imaging of Glycoprotein Non-Metastatic Melanoma B in Triple Negative Breast Cancer: Feasibility of an Antibody-Based Companion Diagnostic Agent
    Marquez-Nostra BV, Lee S, Laforest R, Vitale L, Nie X, Hyrc K, Keler T, Hawthorne T, Hoog J, Li S, Dehdashti F, Ma CX, Lapi SE
    Oncotarget 2017 Nov 1;8(61):104303-104314
  • Serum Thymidine Kinase 1 Activity as a Pharmacodynamic Marker of Cyclin-Dependent Kinase 4/6 Inhibition in Patients With Early-Stage Breast Cancer Receiving Neoadjuvant Palbociclib
    Bagegni N, Thomas S, Liu N, Luo J, Hoog J, Northfelt DW, Goetz MP, Forero A, Bergqvist M, Karen J, Neumuller M, Suh EM, Guo Z, Vij K, Sanati S, Ellis M, Ma CX
    Breast Cancer Res 2017 Nov 21;19(1):123
  • A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, With Anastrozole in Clinical Stage II or III PIK3CA-Mutant ER-Positive and HER2-Negative Breast Cancer
    Ma CX, Suman V, Goetz MP, Northfelt D, Burkard ME, Ademuyiwa F, Naughton M, Margenthaler J, Aft R, Gray R, Tevaarwerk A, Wilke L, Haddad T, Moynihan T, Loprinzi C, Hieken T, Barnell EK, Skidmore ZL, Feng YY, Krysiak K, Hoog J, Guo Z, Nehring L, Wisinski KB, Mardis E, Hagemann IS, Vij K, Sanati S, Al-Kateb H, Griffith OL, Griffith M, Doyle L, Erlichman C, Ellis MJ
    Clin Cancer Res 2017 Nov 15;23(22):6823-6832
  • Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control Through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer
    Haricharan S, Punturi N, Singh P, Holloway KR, Anurag M, Schmelz J, Schmidt C, Lei JT, Suman V, Hunt K, Olson JA Jr, Hoog J, Li S, Huang S, Edwards DP, Kavuri SM, Bainbridge MN, Ma CX, Ellis MJ
    Cancer Discov 2017 Oct;7(10):1168-1183
  • Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer
    Ma CX*, Bose R*, Gao F, Freedman RA, Telli ML, Kimmick G, Winer E, Naughton M, Goetz MP, Russell C, Tripathy D, Cobleigh M, Forero A, Pluard TJ, Anders C, Niravath PA, Thomas S, Anderson J, Bumb C, Banks KC, Lanman RB, Bryce R, Lalani AS, Pfeifer J, Hayes DF, Pegram M, Blackwell K, Bedard PL, Al-Kateb H, Ellis MJC (*co-first author)
    Clin Cancer Res 2017 Oct 1;23(19):5687-5695
  • NCCN Guidelines Insights: Antiemesis, Version 2.2017
    Berger MJ, Ettinger DS, Aston J, Barbour S, Bergsbaken J, Bierman PJ, Brandt D, Dolan DE, Ellis G, Kim EJ, Kirkegaard S, Kloth DD, Lagman R, Lim D, Loprinzi C, Ma CX, Maurer V, Michaud LB, Nabell LM, Noonan K, Roeland E, Rugo HS, Schwartzberg LS, Scullion B, Timoney J, Todaro B, Urba SG, Shead DA, Hughes M
    J Natl Compr Canc Netw 2017 Jul;15(7):883-893
  • Development of a Ki-67-Based Clinical Trial Assay for Neoadjuvant Endocrine Therapy Response Monitoring in Breast Cancer
    Goncalves R*, DeSchryver K*, Ma C*, Tao Y, Hoog J, Cheang M, Crouch E, Dahiya N, Sanati S, Barnes M, Sarian LOZ, Olson J, Allred DC, Ellis MJ (*co-first author)
    Breast Cancer Res Treat 2017 Sep;165(2):355-364
  • Breast Cancer Stage Variation and Survival in Association With Insurance Status and Sociodemographic Factors in US Women 18 to 64 Years Old
    Hsu CD, Wang X, Habif DV Jr, Ma CX, Johnson KJ
    Cancer 2017 Aug 15;123(16):3125-3131
  • CDK4/6 Inhibition Triggers Anti-Tumour Immunity
    Goel S, DeCristo MJ, Watt AC, BrinJones H, Sceneay J, Li BB, Khan N, Ubellacker JM, Xie S, Metzger-Filho O, Hoog J, Ellis MJ, Ma CX, Ramm S, Krop IE, Winer EP, Roberts TM, Kim HJ, McAllister SS, Zhao JJ
    Nature 2017 Aug 24;548(7668):471-475
  • Efficacy of the PARP Inhibitor Veliparib With Carboplatin or as a Single Agent in Patients With Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083
    Somlo G, Frankel PH, Arun BK, Ma CX, Garcia AA, Cigler T, Cream LV, Harvey HA, Sparano JA, Nanda R, Chew HK, Moynihan TJ, Vahdat LT, Goetz MP, Beumer JH, Hurria A, Mortimer J, Piekarz R, Sand S, Herzog J, Van Tongeren LR, Ferry-Galow KV, Chen AP, Ruel C, Newman EM, Gandara DR, Weitzel JN
    Clin Cancer Res 2017 Aug 1;23(15):4066-4076
  • Proteogenomic Integration Reveals Therapeutic Targets in Breast Cancer Xenografts
    Huang KL, Li S, Mertins P, Cao S, Gunawardena HP, Ruggles KV, Mani DR, Clauser KR, Tanioka M, Usary J, Kavuri SM, Xie L, Yoon C, Qiao JW, Wrobel J, Wyczalkowski MA, Erdmann-Gilmore P, Snider JE, Hoog J, Singh P, Niu B, Guo Z, Sun SQ, Sanati S, Kawaler E, Wang X, Scott A, Ye K, McLellan MD, Wendl MC, Malovannaya A, Held JM, Gillette MA, Fenyo D, Kinsinger CR, Mesri M, Rodriguez H, Davies SR, Perou CM, Ma C, Reid Townsend R, Chen X, Carr SA, Ellis MJ, Ding L
    Nat Commun 2017 Mar 28;8:14864
  • 64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients With Metastatic Breast Cancer
    Lee H, Shields AF, Siegel BA, Miller KD, Krop I, Ma CX, LoRusso PM, Munster PN, Campbell K, Gaddy DF, Leonard SC, Geretti E, Blocker SJ, Kirpotin DB, Moyo V, Wickham TJ, Hendriks BS
    Clin Cancer Res 2017 Aug 1;23(15):4190-4202
  • NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast Cancer
    Ma CX, Gao F, Luo J, Northfelt DW, Goetz M, Forero A, Hoog J, Naughton M, Ademuyiwa F, Suresh R, Anderson KS, Margenthaler J, Aft R, Hobday T, Moynihan T, Gillanders W, Cyr A, Eberlein TJ, Hieken T, Krontiras H, Guo Z, Lee MV, Spies NC, Skidmore ZL, Griffith OL, Griffith M, Thomas S, Bumb C, Vij K, Bartlett CH, Koehler M, Al-Kateb H, Sanati S, Ellis MJ
    Clin Cancer Res 2017 Aug 1;23(15):4055-4065
  • Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance)
    Ellis MJ, Suman VJ, Hoog J, Goncalves R, Sanati S, Creighton CJ, DeSchryver K, Crouch E, Brink A, Watson M, Luo J, Tao Y, Barnes M, Dowsett M, Budd GT, Winer E, Silverman P, Esserman L, Carey L, Ma CX, Unzeitig G, Pluard T, Whitworth P, Babiera G, Guenther JM, Dayao Z, Ota D, Leitch M, Olson JA Jr, Allred DC, Hunt K
    J Clin Oncol 2017 Apr 1;35(10):1061-1069
  • Differences in the Mutational Landscape of Triple-Negative Breast Cancer in African Americans and Caucasians
    Ademuyiwa FO, Tao Y, Luo J, Weilbaecher K, Ma CX
    Breast Cancer Res Treat 2017 Feb;161(3):491-499
  • Randomized Phase II Trial of Fulvestrant Alone or in Combination With Bortezomib in Hormone Receptor-Positive Metastatic Breast Cancer Resistant to Aromatase Inhibitors: A New York Cancer Consortium Trial
    Adelson K, Ramaswamy B, Sparano JA, Christos PJ, Wright JJ, Raptis G, Han G, Villalona-Calero M, Ma CX, Hershman D, Baar J, Klein P, Cigler T, Budd GT, Novik Y, Tan AR, Tannenbaum S, Goel A, Levine E, Shapiro CL, Andreopoulou E, Naughton M, Kalinsky K, Waxman S, Germain D
    NPJ Breast Cancer 2016 Dec 14;2:16037
  • Inhibition of Cyclin Dependent Kinase 9 by Dinaciclib Suppresses Cyclin B1 Expression and Tumor Growth in Triple Negative Breast Cancer
    Rajput S, Khera N, Guo Z, Hoog J, Li S, Ma CX
    Oncotarget 2016 Aug 30;7(35):56864-56875
  • A Phase I Study of the AKT Inhibitor MK-2206 in Combination With Hormonal Therapy in Postmenopausal Women With Estrogen Receptor-Positive Metastatic Breast Cancer
    Ma CX, Sanchez C, Gao F, Crowder R, Naughton M, Pluard T, Creekmore A, Guo Z, Hoog J, Lockhart AC, Doyle A, Erlichman C, Ellis MJ
    Clin Cancer Res 2016 Jun 1;22(11):2650-8
  • A Phase I Trial of BKM120 (Buparlisib) in Combination With Fulvestrant in Postmenopausal Women With Estrogen Receptor-Positive Metastatic Breast Cancer
    Ma CX, Luo J, Naughton M, Ademuyiwa F, Suresh R, Griffith M, Griffith OL, Skidmore ZL, Spies NC, Ramu A, Trani L, Pluard T, Nagaraj G, Thomas S, Guo Z, Hoog J, Han J, Mardis E, Lockhart AC, Ellis MJ
    Clin Cancer Res 2016 Apr 1;22(7):1583-91
  • The Feasibility of Using Metacognitive Strategy Training to Improve Cognitive Performance and Neural Connectivity in Women With Chemotherapy-Induced Cognitive Impairment
    Wolf TJ, Doherty M, Kallogjeri D, Coalson RS, Nicklaus J, Ma CX, Schlaggar BL, Piccirillo J
    Oncology 2016;91(3):143-152
  • HER2-Mutated Breast Cancer Responds to Treatment With Single-Agent Neratinib, a Second-Generation HER2/EGFR Tyrosine Kinase Inhibitor
    Ben-Baruch NE, Bose R, Kavuri SM, Ma CX, Ellis MJ
    J Natl Compr Canc Netw 2015 Sep;13(9):1061-4
  • The ALTERNATE Trial: Assessing a Biomarker Driven Strategy for the Treatment of Post-Menopausal Women With ER+/Her2- Invasive Breast Cancer
    Suman VJ, Ellis MJ, Ma CX
    Chin Clin Oncol 2015 Sep;4(3):34
  • Genetic Polymorphism at Val80 (Rs700518) of the CYp19A1 Gene Is Associated With Body Composition Changes in Women on Aromatase Inhibitors for ER (+) Breast Cancer
    Napoli N, Rastelli A, Ma C, Colleluori G, Vattikuti S, Armamento-Villareal R
    Pharmacogenet Genomics 2015 Aug;25(8):377-381
  • Cognitive Impairment After Chemotherapy Related to Atypical Network Architecture for Executive Control
    Piccirillo JF, Hardin FM, Nicklaus J, Kallogjeri D, Wilson M, Ma CX, Coalson RS, Shimony J, Schlaggar BL
    Oncology 2015;88(6):360-8
  • US Breast Cancer Mortality Trends in Young Women According to Race
    Ademuyiwa FO, Gao F, Hao L, Morgensztern D, Aft RL, Ma CX, Ellis MJ
    Cancer 2015 May 1;121(9):1469-76
  • Management of Premenopausal Women With Neoadjuvant Endocrine Therapy: A Single-Institution Experience
    Barbie TU, Ma C, Margenthaler JA
    Ann Surg Oncol 2015 Nov;22(12):3861-5
  • Treatment-Associated Musculoskeletal and Vasomotor Symptoms and Relapse-Free Survival in the NCIC CTG MA.27 Adjuvant Breast Cancer Aromatase Inhibitor Trial
    Stearns V, Chapman JA, Ma CX, Ellis MJ, Ingle JN, Pritchard KI, Budd GT, Rabaglio M, Sledge GW, Le Maitre A, Kundapur J, Liedke PE, Shepherd LE, Goss PE
    J Clin Oncol 2015 Jan 20;33(3):265-71
  • Endocrine Therapy With or Without Inhibition of Epidermal Growth Factor Receptor and Human Epidermal Growth Factor Receptor 2: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Fulvestrant With or Without Lapatinib for Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer - CALGB 40302 (Alliance)
    Burstein HJ, Cirrincione CT, Barry WT, Chew HK, Tolaney SM, Lake DE, Ma C, Blackwell KL, Winer EP, Hudis CA
    J Clin Oncol 2014 Dec 10;32(35):3959-66
  • A Phase I Study of Pegylated Liposomal Doxorubicin and Temsirolimus in Patients With Refractory Solid Malignancies
    Wang-Gillam A, Thakkar N, Lockhart AC, Williams K, Baggstrom M, Naughton M, Suresh R, Ma C, Tan B, Lee W, Jiang X, Mwandoro T, Trull L, Belanger S, Creekmore AN, Gao F, Fracasso PM, Picus J
    Cancer Chemother Pharmacol 2014 Aug;74(2):419-26
  • Safety and Preliminary Evidence of Biologic Efficacy of a Mammaglobin-A DNA Vaccine in Patients With Stable Metastatic Breast Cancer
    Tiriveedhi V, Tucker N, Herndon J, Li L, Sturmoski M, Ellis M, Ma C, Naughton M, Lockhart AC, Gao F, Fleming T, Goedegebuure P, Mohanakumar T, Gillanders WE
    Clin Cancer Res 2014 Dec 1;20(23):5964-75
  • Body Mass Index, Diabetes, and Triple-Negative Breast Cancer Prognosis
    Tait S, Pacheco JM, Gao F, Bumb C, Ellis MJ, Ma CX
    Breast Cancer Res Treat 2014 Jul;146(1):189-97
  • Endocrine-Therapy-Resistant ESR1 Variants Revealed by Genomic Characterization of Breast-Cancer-Derived Xenografts
    Li S, Shen D, Shao J, Crowder R, Liu W, Prat A, He X, Liu S, Hoog J, Lu C, Ding L, Griffith OL, Miller C, Larson D, Fulton RS, Harrison M, Mooney T, McMichael JF, Luo J, Tao Y, Goncalves R, Schlosberg C, Hiken JF, Saied L, Sanchez C, Giuntoli T, Bumb C, Cooper C, Kitchens RT, Lin A, Phommaly C, Davies SR, Zhang J, Kavuri MS, McEachern D, Dong YY, Ma C, Pluard T, Naughton M, Bose R, Suresh R, McDowell R, Michel L, Aft R, Gillanders W, Deschryver K, Wilson RK, Wang S, Mills GB, Gonzalez-Angulo A, Edwards JR, Maher C, Perou CM, Mardis ER, Ellis MJ
    Cell Rep 2013 Sep 26;4(6):1116-30
  • Combined Targeting of mTOR and AKT Is an Effective Strategy for Basal-Like Breast Cancer in Patient-Derived Xenograft Models
    Xu S, Li S, Guo Z, Luo J, Ellis MJ, Ma CX
    Mol Cancer Ther 2013 Aug;12(8):1665-75
  • Genetic Polymorphism at Val80 (Rs700518) of the CYp19A1 Gene Is Associated With Aromatase Inhibitor Associated Bone Loss in Women With ER + Breast Cancer
    Napoli N, Rastelli A, Ma C, Yarramaneni J, Vattikutti S, Moskowitz G, Giri T, Mueller C, Kulkarny V, Qualls C, Ellis M, Armamento-Villareal R
    Bone 2013 Aug;55(2):309-14
  • A Phase I Trial of the IGF-1R Antibody Cixutumumab in Combination With Temsirolimus in Patients With Metastatic Breast Cancer
    Ma CX, Suman VJ, Goetz M, Haluska P, Moynihan T, Nanda R, Olopade O, Pluard T, Guo Z, Chen HX, Erlichman C, Ellis MJ, Fleming GF
    Breast Cancer Res Treat 2013 May;139(1):145-53
  • Racial Differences in Outcomes of Triple-Negative Breast Cancer
    Pacheco JM, Gao F, Bumb C, Ellis MJ, Ma CX
    Breast Cancer Res Treat 2013 Feb;138(1):281-9
  • A Phase II Study of UCN-01 in Combination With Irinotecan in Patients With Metastatic Triple Negative Breast Cancer
    Ma CX, Ellis MJ, Petroni GR, Guo Z, Cai SR, Ryan CE, Lockhart AC, Naughton MJ, Pluard TJ, Brenin CM, Picus J, Creekmore AN, Mwandoro T, Yarde ER, Reed J, Ebbert M, Bernard PS, Watson M, Doyle LA, Dancey J, Piwnica-Worms H, Fracasso PM
    Breast Cancer Res Treat 2013 Jan;137(2):483-92
  • Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer
    Bose R, Kavuri SM, Searleman AC, Shen W, Shen D, Koboldt DC, Monsey J, Goel N, Aronson AB, Li S, Ma CX, Ding L, Mardis ER, Ellis MJ
    Cancer Discov 2013 Feb;3(2):224-37
  • Adjuvant Chemotherapy Decisions in Clinical Practice for Early-Stage Node-Negative, Estrogen Receptor-Positive, HER2-Negative Breast Cancer: Challenges and Considerations
    Nagaraj G, Ma CX
    J Natl Compr Canc Netw 2013 Mar 1;11(3):246-51
  • Mammaglobin-A cDNA Vaccination of Breast Cancer Patients Induces Antigen-Specific Cytotoxic CD4+ICOS(Hi) T Cells
    Tiriveedhi V, Fleming TP, Goedegebuure PS, Naughton M, Ma C, Lockhart C, Gao F, Gillanders WE, Mohanakumar T
    Breast Cancer Res Treat 2013 Feb;138(1):109-18
  • Targeting Chk1 in p53-Deficient Triple-Negative Breast Cancer Is Therapeutically Beneficial in Human-In-Mouse Tumor Models
    Ma CX, Cai S, Li S, Ryan CE, Guo Z, Schaiff WT, Lin L, Hoog J, Goiffon RJ, Prat A, Aft RL, Ellis MJ, Piwnica-Worms H
    J Clin Invest 2012 Apr 2;122(4):1541-52
  • TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer
    Carey LA, Rugo HS, Marcom PK, Mayer EL, Esteva FJ, Ma CX, Liu MC, Storniolo AM, Rimawi MF, Forero-Torres A, Wolff AC, Hobday TJ, Ivanova A, Chiu WK, Ferraro M, Burrows E, Bernard PS, Hoadley KA, Perou CM, Winer EP
    J Clin Oncol 2012 Jul 20;30(21):2615-23
  • Phase II Trial of Temsirolimus in Patients With Metastatic Breast Cancer
    Fleming GF, Ma CX, Huo D, Sattar H, Tretiakova M, Lin L, Hahn OM, Olopade FO, Nanda R, Hoffman PC, Naughton MJ, Pluard T, Conzen SD, Ellis MJ
    Breast Cancer Res Treat 2012 Nov;136(2):355-63
  • Neoadjuvant Chemotherapy Is Associated With Improved Survival Compared With Adjuvant Chemotherapy in Patients With Triple-Negative Breast Cancer Only After Complete Pathologic Response
    Fisher CS, Ma CX, Gillanders WE, Aft RL, Eberlein TJ, Gao F, Margenthaler JA
    Ann Surg Oncol 2012 Jan;19(1):253-8
  • A Phase 1 Study of UCN-01 in Combination With Irinotecan in Patients With Resistant Solid Tumor Malignancies
    Fracasso PM, Williams KJ, Chen RC, Picus J, Ma CX, Ellis MJ, Tan BR, Pluard TJ, Adkins DR, Naughton MJ, Rader JS, Arquette MA, Fleshman JW, Creekmore AN, Goodner SA, Wright LP, Guo Z, Ryan CE, Tao Y, Soares EM, Cai SR, Lin L, Dancey J, Rudek MA, McLeod HL, Piwnica-Worms H
    Cancer Chemother Pharmacol 2011 Jun;67(6):1225-37
  • Preclinical Modeling of Combined Phosphatidylinositol-3-Kinase Inhibition With Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer
    Sanchez CG*, Ma CX*, Crowder RJ, Guintoli T, Phommaly C, Gao F, Lin L, Ellis MJ (*equal contribution)
    Breast Cancer Res 2011 Mar 1;13(2):R21
  • Aromatase Gene Polymorphisms Are Associated With Survival Among Patients With Cardiovascular Disease in a Sex-Specific Manner
    Beitelshees AL, Johnson JA, Hames ML, Gong Y, Cooper-Dehoff RM, Wu J, Cresci S, Ma CX, Pepine CJ, Province MA, Spertus JA, McLeod HL
    PLoS One 2010 Dec 10;5(12):e15180
  • High Prevalence of Low Vitamin D and Musculoskeletal Complaints in Women With Breast Cancer
    Napoli N, Vattikuti S, Ma C, Rastelli A, Rayani A, Donepudi R, Asadfard M, Yarramaneni J, Ellis M, Armamento-Villareal R
    Breast J 2010 Nov;16(6):609-16
  • Effect of Zoledronic Acid on Disseminated Tumour Cells in Women With Locally Advanced Breast Cancer: An Open Label, Randomised, Phase 2 Trial
    Aft R, Naughton M, Trinkaus K, Watson M, Ylagan L, Chavez-MacGregor M, Zhai J, Kuo S, Shannon W, Diemer K, Herrmann V, Dietz J, Ali A, Ellis M, Weiss P, Eberlein T, Ma C, Fracasso PM, Zoberi I, Taylor M, Gillanders W, Pluard T, Mortimer J, Weilbaecher K
    Lancet Oncol 2010 May;11(5):421-8
  • A Study of Paclitaxel, Carboplatin, and Bortezomib in the Treatment of Metastatic Malignant Melanoma: A Phase 2 Consortium Study
    Croghan GA, Suman VJ, Maples WJ, Albertini M, Linette G, Flaherty L, Eckardt J, Ma C, Markovic SN, Erlichman C
    Cancer 2010 Jul 15;116(14):3463-8
  • Bortezomib, Paclitaxel, and Carboplatin as a First-Line Regimen for Patients With Metastatic Esophageal, Gastric, and Gastroesophageal Cancer: Phase II Results From the North Central Cancer Treatment Group (N044B)
    Jatoi A, Dakhil SR, Foster NR, Ma C, Rowland KM Jr, Moore DF Jr, Jaslowski AJ, Thomas SP, Hauge MD, Flynn PJ, Stella PJ, Alberts SR
    J Thorac Oncol 2008 May;3(5):516-20
  • A Comprehensive Examination of CYp19 Variation and Breast Density
    Olson JE, Ma CX, Pelleymounter LL, Schaid DJ, Pankratz VS, Vierkant RA, Fredericksen ZS, Ingle JN, Wu Y, Couch F, Sellers TA, Weinshilboum RM, Vachon CM
    Cancer Epidemiol Biomarkers Prev 2007 Mar;16(3):623-5
  • A Comprehensive Examination of CYp19 Variation and Risk of Breast Cancer Using Two Haplotype-Tagging Approaches
    Olson JE, Ingle JN, Ma CX, Pelleymounter LL, Schaid DJ, Pankratz VS, Vierkant RA, Fredericksen ZS, Wu Y, Couch FJ, Vachon CM, Sellers TA, Weinshilboum RM
    Breast Cancer Res Treat 2007 Apr;102(2):237-47
  • A Phase I and Pharmacologic Study of Sequences of the Proteasome Inhibitor, Bortezomib (PS-341, Velcade), in Combination With Paclitaxel and Carboplatin in Patients With Advanced Malignancies
    Ma C, Mandrekar SJ, Alberts SR, Croghan GA, Jatoi A, Reid JM, Hanson LJ, Bruzek L, Tan AD, Pitot HC, Erlichman C, Wright JJ, Adjei AA
    Cancer Chemother Pharmacol 2007 Feb;59(2):207-15
  • A Phase II Trial of a Combination of Pemetrexed and Gemcitabine in Patients With Metastatic Breast Cancer: An NCCTG Study
    Ma CX, Steen P, Rowland KM, Niedringhaus RD, Fitch TR, Kugler JW, Hillman DW, Perez EA, Ingle JN, Adjei AA
    Ann Oncol 2006 Feb;17(2):226-31
  • Human Aromatase: Gene Resequencing and Functional Genomics
    Ma CX, Adjei AA, Salavaggione OE, Coronel J, Pelleymounter L, Wang L, Eckloff BW, Schaid D, Wieben ED, Adjei AA, Weinshilboum RM
    Cancer Res 2005 Dec 1;65(23):11071-82
  • Randomized Phase II Trial of Three Schedules of Pemetrexed and Gemcitabine as Front-Line Therapy for Advanced Non-Small-Cell Lung Cancer
    Ma CX, Nair S, Thomas S, Mandrekar SJ, Nikcevich DA, Rowland KM, Fitch TR, Windschitl HE, Hillman SL, Schild SE, Jett JR, Obasaju C, Adjei AA
    J Clin Oncol 2005 Sep 1;23(25):5929-37
  • Large Cell Carcinoma With Calcitonin and Vasoactive Intestinal Polypeptide-Associated Verner-Morrison Syndrome
    Pratz KW, Ma C, Aubry MC, Vrtiska TJ, Erlichman C
    Mayo Clin Proc 2005 Jan;80(1):116-20
  • Acquired Fanconi Syndrome Is an Indolent Disorder in the Absence of Overt Multiple Myeloma
    Ma CX, Lacy MQ, Rompala JF, Dispenzieri A, Rajkumar SV, Greipp PR, Fonseca R, Kyle RA, Gertz MA
    Blood 2004 Jul 1;104(1):40-2
  • Imatinib Mesylate-Induced Interstitial Pneumonitis
    Ma CX, Hobday TJ, Jett JR
    Mayo Clin Proc 2003 Dec;78(12):1578-9
  • Recognition of Multiple Patterns of DNA Sites by Drosophila Homeodomain Protein Bicoid
    Yuan D, Ma X, Ma J
    J Biochem (Tokyo) 1999 Apr;125(4):809-17
  • Contributions to Gene Activation by Multiple Functions of Bicoid
    Ma X, Yuan D, Scarborough T, Ma J
    Biochem J 1999 Mar 1;338 ( Pt 2):447-55
  • The Drosophila Morphogenetic Protein Bicoid Binds DNA Cooperatively
    Ma X, Yuan D, Diepold K, Scarborough T, Ma J
    Development 1996 Apr;122(4):1195-206
  • Sequences Outside the Homeodomain of Bicoid Are Required for Protein-Protein Interaction
    Yuan D, Ma X, Ma J
    J Biol Chem 1996 Aug 30;271(35):21660-5

Invited Publications

  • Breast Cancer
    Clifton K, Ademuyiwa FO, Bose R, Ma CX
    In: DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology Review, 5th Edition (Morgensztern D, Govindan R, Devarakonda S, Trikalinos NA, Editors), Wolters Kluwer, Philadelphia, 2022
  • Breast Cancer
    Xi J, Ma CX, Clifton K
    In: The Washington Manual of Oncology, 4th Edition (Morgensztern D, Ghobadi A, Govindan R, Editors), Wolters Kluwer, Philadelphia, 2022
  • Clinical Challenges in the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: A Literature Review
    Nagaraj G, Ma CX
    Adv Ther 2021 Jan;38(1):109-136
  • Sequencing Endocrine Therapy for Metastatic Breast Cancer: What Do We Do After Disease Progression on a CDK4/6 Inhibitor?
    Xi J, Ma CX
    Curr Oncol Rep 2020 May 16;22(6):57
  • PI3K Inhibitors in Breast Cancer Therapy
    Ellis H, Ma CX
    Curr Oncol Rep 2019 Dec 11;21(12):110
  • Neoadjuvant Endocrine Therapy: Who Benefits Most?
    Grossman J, Ma C, Aft R
    Surg Oncol Clin N Am 2018 Jan;27(1):121-140
  • The Role of Neratinib in HER2-Driven Breast Cancer
    Cherian MA, Ma CX
    Future Oncol 2017 Sep;13(22):1931-1943
  • New Insights in Estrogen Receptor Biology and Implication for Treatment
    Oza A, Ma CX
    Current Breast Cancer Reports - Springer (9-1), 2017, Feb 14. E pub
  • Beyond Genomics: Biologic Insights From the CPTAC Proteogenomic Analysis of Breast Cancer
    Rajput S, Ma CX
    Translational Cancer Research 2016 Oct;5(Suppl 4):S713-S715
  • Treating and Managing Future Risk in Women With Hereditary Breast Cancer
    Ma CX
    Cancer News in Context, July 13, 2016
  • Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer
    Hernandez-Aya LF, Ma CX
    Breast Diseases: A Year Book Quarterly. 2016
  • Chemotherapy Principles of Managing Stage IV Breast Cancer in the United States
    Hernandez-Aya LF, Ma CX
    Chin Clin Oncol 2016 Jun;5(3):42
  • Prognostic and Predictive Biomarkers of Endocrine Responsiveness for Estrogen Receptor Positive Breast Cancer
    Ma CX, Bose R, Ellis MJ
    Adv Exp Med Biol 2016;882:125-54
  • Improving Response to Hormone Therapy in Breast Cancer: New Targets, New Therapeutic Options
    Rugo HS, Vidula N, Ma C
    Am Soc Clin Oncol Educ Book 2016;35:e40-54
  • Breast Cancer, Chapter 24
    Ademuyiwa F, Bose R, Ma CX
    In: DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology Review, 4e
  • Neratinib in Early-Stage HER2-Positive Breast Cancer
    Cherian MA, Ma CX
    Breast Diseases: A Year Book Quarterly. 2015 December
  • DCIS: Time to Change Our Standard of Care?
    Ma CX
    Oncology Times 2015 August
  • Revisiting the Estrogen Receptor Pathway and Its Role in Endocrine Therapy for Postmenopausal Women With Estrogen Receptor-Positive Metastatic Breast Cancer
    Nagaraj G, Ma C
    Breast Cancer Res Treat 2015 Apr;150(2):231-42
  • The PI3K Pathway as a Therapeutic Target in Breast Cancer
    Ma CX
    American Journal of Hematology/Oncology. 2015 March
  • Mechanisms of Aromatase Inhibitor Resistance
    Ma CX, Reinert T, Chmielewska I, Ellis MJ
    Nat Rev Cancer 2015 Apr 24;15(5):261-75
  • Key Breast Cancer Takeaways From ASCO 2015
    Ma CX
    Oncology Times 2015 June 29
  • Key Breast Cancer Takeaways From Asco 2014
    Ma CX
    Oncology Times 2014 June 29
  • Chapter 14: Breast Cancer
    Ademuyiwa F, Suresh R, Ellis MJ, Ma CX
    In: Washington Manual of Oncology 4th Edition, Lippincott Williams & Wilkens 2014
  • Metastatic Breast Cancer: Best Practices Based on Cancer Subtypes
    Ma CX
    Young Women’s Breast Cancer Program in St. Louis Magazine. 2014
  • Best Breast Cancer Research 2013
    Ma CX
    Oncology Times 2014 Jan 24
  • The Cancer Genome Atlas: Clinical Applications for Breast Cancer
    Ma CX, Ellis MJ
    Oncology (Williston Park) 2013 Dec;27(12):1263-9, 1274-9
  • Incorporating Genomics Into Breast Cancer Clinical Trials and Care
    Tabchy A, Ma CX, Bose R, Ellis MJ
    Clin Cancer Res 2013 Dec 1;19(23):6371-9
  • Neoadjuvant Therapy in Operable Breast Cancer: Application to Triple Negative Breast Cancer
    Ademuyiwa FO, Ellis MJ, Ma CX
    J Oncol 2013;2013:219869
  • Chapter 19: Genomic Events in Breast Cancer Progression
    Goncalves R, Cakar B, Bose R, Ma CX, Ellis MJ
    In: Disease of the Breast, 5th Edition
  • Targeted Therapy for Breast Cancer
    Mohamed A, Krajewski K, Cakar B, Ma CX
    Am J Pathol 2013 Oct;183(4):1096-112
  • PI3K Inhibitors in Breast Cancer Treatment
    Pacheco JM, Ma CX
    The International Journal of Targeted Therapies in Cancer 2013 May 7
  • Biology of Breast Cancer - Better Therapy Promised for Triple Negative Breast Cancer
    Ma CX
    Oncology Times 2013 Jan 6
  • Mammalian Target of Rapamycin Inhibitors in Breast Cancer Therapy CML
    Ezewuiro O, Ma CX, Fleming GF
    Breast Cancer 2012;24(4):117–30
  • The Natural History of Hormone Receptor-Positive Breast Cancer: Attempting to Decipher an Intriguing Concept
    Nagaraj G, Ellis MJ, Ma CX
    Oncology (Williston Park) 2012 Aug;26(8):696-7, 700
  • Endocrine Resistance in Breast Cancer: Molecular Pathways and Rational Development of Targeted Therapies
    Roop RP, Ma CX
    Future Oncol 2012 Mar;8(3):273-92
  • Use of Neoadjuvant Data to Design Adjuvant Endocrine Therapy Trials for Breast Cancer
    Goncalves R, Ma C, Luo J, Suman V, Ellis MJ
    Nat Rev Clin Oncol 2012 Feb 28;9(4):223-9
  • Molecular Basis of Triple Negative Breast Cancer and Implications for Therapy
    Peddi PF, Ellis MJ, Ma C
    Int J Breast Cancer 2012;2012:217185
  • PARP Inhibitors and Their Evolving Role in Breast Cancer
    Roop RP, Ma CX, Ellis MJ
    Oncology (Williston Park) 2011 Oct;25(11):1033-4
  • Estrogen and Progesterone Receptors in Breast Cancer
    Ma CX
    Clin Adv Hematol Oncol 2011 May;9(5):385-6
  • Systemic Therapy for Metastatic Breast Cancer: Endocrine Therapy (Online Chapter)
    Ellis M, Hayes D, Naughton M, Ma CX
    UpToDate 19.2 2011
  • Importance of PI3-Kinase Pathway in Response/Resistance to Aromatase Inhibitors
    Ma CX, Crowder RJ, Ellis MJ
    Steroids 2011 Jul;76(8):750-2
  • Death by Releasing the Breaks: CHK1 Inhibitors as Cancer Therapeutics
    Ma CX, Janetka JW, Piwnica-Worms H
    Trends Mol Med 2011 Feb;17(2):88-96
  • Optimal Selection of Adjuvant Chemotherapy in Patients With Breast Cancer (Chapter)
    Ma CX
    Epocrates 2010
  • Molecular Profiling of Triple Negative Breast Cancer
    Ma CX, Luo J, Ellis MJ
    Breast Dis 2010 Jan 1;32(1):73-84
  • Hedgehog Pathway Inhibitors: Potential Applications in Breast Cancer (Review)
    Chia YH, Ma CX
    Current Breast Cancer Report 2010;3(1):15-23
  • Neoadjuvant Endocrine Therapy in Primary Breast Cancer: Indications and Use as a Research Tool
    Chia YH, Ellis MJ, Ma CX
    Br J Cancer 2010 Sep 7;103(6):759-64
  • Commentary on "Functional Genetic Polymorphisms in the Aromatase Gene CYp19 Vary the Response of Breast Cancer Patients to Neoadjuvant Therapy With Aromatase Inhibitors. Cancer Research 70 (1):319-28"
    Ma CX, Ellis MJ
    Breast Diseases: A Year Book Quarterly 2010;21(3):266-7
  • Neoadjuvant Endocrine Therapy for Breast Cancer
    Chawla JS, Ma CX, Ellis MJ
    Surg Oncol Clin N Am 2010 Jul;19(3):627-638
  • Updates on Adjuvant Trastuzumab Therapy for Breast Cancer
    Ma CX
    China Medical Tribute B4-B5 2010 March 18; B4-B5
  • Commentary on "Letrozole Therapy Alone or in Sequence With Tamoxifen in Women With Breast Cancer. N Engl J Med 361(8):766-76"
    Chia YH, Ma CX, Ellis MJ
    Breast Diseases: A Year Book Quarterly 2010;21(2):168-9
  • Neoadjuvant Endocrine Therapy for Breast Cancer
    Chia YH, Ma CX, Ellis MJ
    Breast Diseases: A Year Book Quarterly 2009;20(4):355-7
  • Commentary on "Cohort Study Examining Tamoxifen Adherence and Its Relationship to Mortality in Women With Breast Cancer. Br J Cancer 99:1763-8"
    Chia YH, Ma CX
    Breast Diseases: A Year Book Quarterly 2009;20(3):327-8
  • Commentary on "Double-Blind, Randomized Placebo Controlled Trial of Fulvestrant Compared With Exemestane After Prior Nonsteroidal Aromatase Inhibitor Therapy in Postmenopausal Women With Hormone Receptor–positive, Advanced Breast Cancer: Results From EFECT. J Clin Oncol 26:1664-70"
    Chia YH, Ma CX
    Breast Diseases: A Year Book Quarterly 2009;20(1):94-5
  • An Update on Adjuvant Therapy With Trastuzumab, Part 3
    Chia YH, Ma CX
    E-Updates in HER2 Targeting in Breast Cancer 2009; 3
  • An Update on the Use of Lapatinib, Part 3
    Ma CX, Chia YH
    E-Updates in HER2 Targeting in Breast Cancer 2009; 3
  • Predicting Endocrine Therapy Responsiveness in Breast Cancer
    Ma CX, Sanchez CG, Ellis MJ
    Oncology (Williston Park) 2009 Feb;23(2):133-42
  • Letrozole in the Neoadjuvant Setting: The P024 Trial
    Ellis MJ, Ma C
    Breast Cancer Res Treat 2007;105 Suppl 1:33-43
  • Femara and the Future: Tailoring Treatment and Combination Therapies With Femara
    Ellis M, Ma C
    Breast Cancer Res Treat 2007;105 Suppl 1:105-15
  • Commentary on "A Meta-Analysis on the Interaction Between HER-2 Expression and Response to Endocrine Treatment in Advanced Breast Cancer, Clinical Cancer Research 11(13):4741-8"
    Ma CX, Ellis MJ
    Breast Diseases, A Year Book Quarterly 2006;17(3):282-3
  • Commentary on "Can Molecular Markers Predict When to Implement Treatment with Aromatase Inhibitors in Invasive Breast Cancer? Clinical Cancer Research 11(13):4835-42"
    Ma CX, Ellis MJ
    Breast Diseases, A Year Book Quarterly 2006:17(3):286-7
  • Neoadjuvant Endocrine Therapy for Locally Advanced Breast Cancer
    Ma CX, Ellis MJ
    Semin Oncol 2006 Dec;33(6):650-6
  • Endocrine Therapy Resistance: Molecular Predictive Models and Mechanism-Based Solutions
    Ma CX, Ellis MJ
    Translating advances in hormonal therapies for breast cancer into clinical practice: a continuing education monograph for oncology professionals by Meniscus, Aug 2006: pp 25-34